Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity.

Journal of diabetes science and technology - 1 Mar 2025

Klein Matthew P, Akturk Halis Kaan, Snell-Bergeon Janet K, Shah Viral N

Abstract excerpt

BACKGROUND: Once weekly Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) have been shown to improve glycemic outcomes and cause significant weight loss. However, 9% to 27% of individuals have little or no response to these drugs. In this article, we investigated the efficacy of GLP-1 RA therapy among adults with type 1 diabetes and obesity likely related to genetic mutations compared with obesity likely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Diabetes Mellitus, Type 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Glycated Hemoglobin

Share to Hypoglycemic Agents

Share to Obesity

Share to Treatment Outcome

Share to Weight Loss

Source

Open in PubMed Open full text

Identifiers

PMID: 38629877
DOI: 10.1177/19322968241245680
PMCID: PMC11571401

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity.PMID 38629877Read ↗

Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiencySemantic proximity Read ↗

Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanksSemantic proximity Read ↗

Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight lossSemantic proximity Read ↗

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read ↗

Genetic predictors of GLP1 receptor agonist weight loss and side effects.Semantic proximity Read ↗

Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)Semantic proximity Read ↗

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.Semantic proximity Read ↗

Tirzepatide for LipodystrophySemantic proximity Read ↗

From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?Semantic proximity Read ↗

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.Semantic proximity Read ↗

Monogenic Obesity; Using Drugs to Bypass the Problem.Semantic proximity Read ↗

Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.